Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.
Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L. Ivagnès A, et al. Among authors: iribarren k. Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018. Oncoimmunology. 2017. PMID: 30524877 Free PMC article.
Dual roles of TLR7 in the lung cancer microenvironment.
Dajon M, Iribarren K, Cremer I. Dajon M, et al. Among authors: iribarren k. Oncoimmunology. 2015 Jan 9;4(3):e991615. doi: 10.4161/2162402X.2014.991615. eCollection 2015 Mar. Oncoimmunology. 2015. PMID: 25949912 Free PMC article.
Anticancer effects of anti-CD47 immunotherapy in vivo.
Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G. Iribarren K, et al. Oncoimmunology. 2018 Dec 11;8(3):1550619. doi: 10.1080/2162402X.2018.1550619. eCollection 2019. Oncoimmunology. 2018. PMID: 30723582 Free PMC article.
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L. Iribarren K, et al. Oncoimmunology. 2015 Sep 2;5(3):e1088631. doi: 10.1080/2162402X.2015.1088631. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141345 Free PMC article. Review.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Routy B, et al. Among authors: iribarren k. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. Science. 2018. PMID: 29097494
Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells.
Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I. Dajon M, et al. Among authors: iribarren k. Oncoimmunology. 2018 Oct 11;8(1):e1505174. doi: 10.1080/2162402X.2018.1505174. eCollection 2019. Oncoimmunology. 2018. PMID: 30546943 Free PMC article.
Epigenetic anticancer agents cause HMGB1 release in vivo.
Liu P, Zhao L, Loos F, Iribarren K, Kepp O, Kroemer G. Liu P, et al. Among authors: iribarren k. Oncoimmunology. 2018 Feb 14;7(6):e1431090. doi: 10.1080/2162402X.2018.1431090. eCollection 2018. Oncoimmunology. 2018. PMID: 29872561 Free PMC article.
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, Pietrantonio F, Ferrere G, Fahrner JE, Le Chatellier E, Pons N, Galleron N, Roume H, Duong CPM, Mondragón L, Iribarren K, Bonvalet M, Terrisse S, Rauber C, Goubet AG, Daillère R, Lemaitre F, Reni A, Casu B, Alou MT, Alves Costa Silva C, Raoult D, Fizazi K, Escudier B, Kroemer G, Albiges L, Zitvogel L. Derosa L, et al. Among authors: iribarren k. Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4. Eur Urol. 2020. PMID: 32376136 Free article.
26 results